BAB 5. KESIMPULAN DAN SARAN
5.2. SARAN
1. Perlunya peningkatan pelayanan dasar untuk parameter kanker ovarium guna peningkatan angka kemampuan bertahan hidup.
2. Edukasi pasien paska penatalaksanaan mengenai kesadaran pasien untuk kontrol kembali secara berkala.
DAFTAR PUSTAKA
1. Depkes R.I No.331/Menkes/SK/V/2006, Rencana Strategi Departement Kesehatan tahun 2005-2009, Departement Kesehatan tahun 2005-2009, Departemen Kesehatan R.I. Jakarta
2. Hardiman A, Noviani R, dkk. Kebijakan dan Pokok – pokok Kegiatan Pengendalian Penyakit Kanker di Indonesia. Rumah Sakit Kanker Darmais. Indonesia Journal of Cancer. Volume 1, No 2.Jakarta. April – Juni 2007
3. Mori M., Harabuchi I., Miyake H., Casagrande J. T., Henderson B. E., Ross R. K. Reproductive, genetic, and dietary risk factors for ovarian cancer. Am. J. Epidemiol.,1988;128: 771-777.
4. Whittemore A. S., Harris R., Itnyre J., Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 U.S. case-control studies. II. Invasive epithelial ovarian cancers in white women. Am. J. Epidemiol, 1992,1184-1203.
5. Survailance Epidemiology and End Result Cancer Statistics Review, 2007. Available from: www.cancer.gov
6. Cigna HealthCare Coverage Position,2007. Available from:
www.cigna.com
7. Qazi Faridullah et al. The treatment of epithelial Ovarian Cancer. CA-A Cancer Journal for Clinicians. 1995; 45: 88 – 101
8. CW, Helm. Malignant Lesions of The Ovaries. Emedicine. Available from:
9. Molly A. Brewer, Karen Johnson, Michele Follen, David Gershenson, and Robert Bast, Jr. Prevention of Ovarian Cancer: Intraepithelial Neoplasia Clin. Cancer Res. 2003 9: 20-30.
10. Barnes M.N., Grizzle W.E., Grubbs C.J., Partridge E.E., Paradigms for Primary Prevention of Ovarian Carcinoma. CA Cancer J Clin 2002;52:216-225.
11. Farid Aziz dkk, Onkologi Ginekologi edisi pertama; Yayasan Bina Pustaka Sarwono Prawiroharjo,Jakarta 2006; 469 – 527.
12. Sahil, M.F. Penatalaksanaan Kanker Ovarium Pada Wanita Usia Muda Dengan Mempertahankan fungsi Ovarium; Pidato pengukuhan jabatan guru besar tetap dalam bidang ilmu Onkologi Ginekologi pada Fakultas Kedokteran USU,2007
13. M.O. Nicoletto, S. Tumolo, C. Falci, and friends. A Randomized Study of Ephitelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission. International Journal of Medicine.2004. Available from:
www.medsci.org
14. Ephitelial Ovarian Cancer. Scottish Interoleegiate Guidelines Network. 2003. Available from: www.sign.ac.uk
15. A.E. Guppy,P.D Nathan, G.J.S. Rustin; Epithelial Ovarian Cancer; A Review of Current Management; Clincal Oncology 2005
16. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Ovarian Cancer, 2008. Available from:
18. Aletti GD et al. Current Management Strategies for Ovarian Cancer. Mayo Clin Proc,2007. Available from: www.mayoclinicproceedings.com
19. Types of Ovarian Cancer. Ovarian Cancer Original Resources. 15 Aug
1999.Available from:
www.oncologychannel.com/ovariancancer/types.html
20. Berek JS,Hacker NF.Eds. Practical by gynaecologic Oncology. Second ed. William and Wilkins. 4th edition.1994; 443 – 536
21. Berek JS, Adashi EY, Hillard PA.Eds. Novak’s gynaecology 12th
ed,William and Wilkins, 1996.
22. Ovarian Cancer. American Cancer Society. Available from:
www.cancer.gov
23. Salazar H., Godwin A. K., Daly M. B., Laub P. B., Hogan W. M., Rosenblum N., Boente M. P., Lynch H. T., Hamilton T. C. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J. Natl. Cancer Inst. (Bethesda), 1996;810-1820.
24. NIH Consensus Statement. Ovarian Cancer: Screening, Treatment, and Followup. Natinal Institutes of Health. Vol 12, No 3. April 1994.
25. New Directions in Ovarian Cancer Research. Report of the Strategic Planning Conference. National Cancer Institute Society of Gynecologic Oncologists Public Health Service Office of Women’s Health December 8-9 2007.
26. Annekatrin Lukanova and Rudolf Kaaks; Endogenous Hormones and Ovarian Cancer: Epidemiology and Current Hypotheses, Departement of Obsterics and Gynaecology, New York University of Medicine.2005
27. Luigi Cobellis et al; From Biology to Biochemical and Biophysical Diagnostic Tools of Ovarian Tumor, Departement Obstetrics and Reproductive Medicine, Section of Obstetrics and Gynecology University of Siena,Italy.2001.
28. Le-Ming Shis and Robert J.Kurman; Ovarian Tumorigenesis, American Journal of Pathology. Vol 164. No 5, May 2004.
29. Choi JH. Ovarian Epithelial Cancer: Etiology and Pathogenesis. Biowave 2008;4.
30. Rosenberg L, Palmer JR, Rao RS, et al. A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2000;9:933– 937.
31. Gross TP, Schlesselman JJ, Stadel BV, et al. The risk of epithelial ovarian cancer in short-term users of oral contraceptives. Am J Epidemiol 1992;136:46–53.
32. Hartge P, Whittemore A, Itnyre J, et al. Rates and risks of ovarian cancer in subgroups of white women in the United States. The Collaborative Ovarian Cancer Group. Obstet Gynecol 1994;84:760–764.
33. Ness RB, Grisso JA, Klapper J, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions. Am J Epidemiol 2000;152:233–241.
34. Schildkraut JM, Calingaert B, Marchbanks PA, et al. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl
35. John EM, Whittemore AS, Harris R, et al. Characteristics relating to ovarian cancer risk: Collaborative analysis of seven US case control studies. Epithelial ovarian cancer in black women. Collaborative Ovarian Cancer Group. J Natl Cancer Inst 1993;85:142–14.
36. Look, k, y. Epidemiology, Etiology, and Screening of Ovarian Cancer. In Ovarian Cancer. 2nd edition. Rubin S, C. Lippincott Williams and Wilkins, 2001: 167 – 77.
37. Whysner, J et al. Perineal Application of Talc and Constrach Powders: Evaluation of Ovarin Cancer Risk. In AJOG Reviews. 2000 : 720 – 24. 38. Walker, G, R, et al. Family History of Cancer, Oral Contrceptiveuse and
Ovarian Canver Risk. Sylverter Comprehensive Cancer center and The Departement of Epidemiology and Public Health University of Miami School of Medicine. July 2001 : 8 – 14.
39. PhD, Godard, B, et al. Risk Factors For Familial and Sporadic Ovarian Cancer Among French Canadians : A Case Control Study. Epidemiology Research Unit Montreal General Hospital Mc Gill University. 1998 : 403 – 10.
40. Hoskin, W, J. Basic Sciene of Gynaecoloic Oncology. Lippincott Williams and Wilkins. 2000 : 9 – 12.
41. Schilder J, M et al. Hereditary Ovarian Cancer : Clinical Syndroma and Management. In Ovarian Cancer. 2nd edition. Rubin S, C. Lippincott Williams and Wilkins. 2001 : 181 – 200.
42. Novak ER, Wood Ruff D. Prymary Carcinoma of The ovary. In Novak’s Gynecology and Obstetric Pathology. 5th Edition. WB Saunders : 347 – 63.